Prognosis following Upper Gastrointestinal Bleeding

Stephen E. Roberts*, Lori A. Button, John G. Williams

College of Medicine, Swansea University, Swansea, United Kingdom

Abstract

Background: Upper gastrointestinal (GI) bleeding is one of the most common, high risk emergency disorders in the western world. Almost nothing has been reported on longer term prognosis following upper GI bleeding. The aim of this study was to establish mortality up to three years following hospital admission with upper GI bleeding and its relationship with aetiology, co-morbidities and socio-demographic factors.

Methods: Systematic record linkage of hospital inpatient and mortality data for 14,212 people in Wales, UK, hospitalised with upper GI bleeding between 1999 and 2004 with three year follow-up to 2007. The main outcome measures were mortality rates, standardised mortality ratios (SMRs) and relative survival.

Results: Mortality at three years was 36.7% overall, based on 5215 fatalities. It was highest for upper GI malignancy (95% died within three years) and varices (52%). Compared with the general population, mortality was increased 27-fold during the first month after admission. It fell to 4.3 by month four, but remained significantly elevated during every month throughout the three years following admission. The most important independent prognostic predictors of mortality at three years were older age (mortality increased 53 fold for people aged 85 years and over compared with those under 40 years); oesophageal and gastric/duodenal malignancy (48 and 32 respectively) and gastric varices aetiologies (2.8) when compared with other bleeds; non-upper GI malignancy, liver disease and renal failure co-morbidities (15, 7.9 and 3.9); social deprivation (29% increase for quintile V vs I); incident bleeds as an inpatient (31% vs admitted with bleeding) and male patients (25% vs female).

Conclusion: Our study shows a high late as well as early mortality for upper GI bleeding, with very poor longer term prognosis following bleeding due to malignancies and varices. Aetiologies with the worst prognosis were often associated with high levels of social deprivation.

Introduction

Upper gastrointestinal (GI) bleeding is one of the most important high risk emergency disorders in the Western world. In the UK alone, it leads to approximately 25,000 inpatient admissions annually, with a high mortality rate that varies from about 3% to 18% across hospitals each year [1,2]. The main causes of upper GI bleeds include peptic ulcer, gastritis, oesophagitis, oesophageal varices, upper GI malignancies and Mallory-Weiss tear [1–6]. The contributions of these different aetiologies have changed over time in many countries, for example, following H. pylori eradication therapy for peptic ulcer and changes over time in alcohol consumption.

Upper GI bleeding has been the subject of many recent audits and other studies that have investigated short term mortality (mainly as an inpatient or at 30 days post admission) [3–19], and explored how it is affected by factors such as aetiology, admission to a dedicated bleed unit, management approach, week day of admission and provision of out of hours diagnostic and therapeutic endoscopy services. Almost nothing has been reported about longer term prognosis following upper gastrointestinal bleeding [20].

The main objectives of this study were, firstly, to establish mortality up to three years following hospital admission with upper GI bleeding and, secondly, to determine how it is related to aetiology, co-morbidities and socio-demographic factors, including social deprivation.

Methods

Study design

For this study, we used a retrospective cohort design for all people in Wales, UK (population 3.0 million) who were hospitalised with upper GI bleeding between 1999 and 2004, with three year follow up to 2007. The study was based on hospital inpatient data, from the Patient Episode Database for Wales (PEDW), with systematic record linkage to death certificate data from the National Health Service (NHS) Welsh Administrative Register, as part of the Secure Anonymised Information Linkage (SAIL) databank [21–23]. As described previously [17,21,22],
PEDW covers inpatient and day case admissions to all NHS hospitals across 22 local health authorities and has been used as the basis of many previous published studies [17,23–29]. The systematic record linkage of inpatient and mortality data enables deaths following discharge from hospital to be identified and included with inhospital deaths. In order to obtain information on the causes of the deaths, we also record linked to death certificate data from the Office for National Statistics (causes of death available from January 2003).

Ethics statement
Ethical approval and patient consent for the study data (Patient Episode Database for Wales and National Health Service Welsh Administrative Register) were not required. This data is publicly available to other researchers. We were advised by the National Research Ethics Service (NRES) that ethical approval and written patient consent were not required as we were using fully anonymised data, which we had obtained approval from the Information Governance Review Panel (IGRP) to use in this study. The IGRP is represented by NRES, the British Medical Association Ethics Advisor, the Cadicott Guardian and NHS Wales Informatics Service.

Setting
The study covered admissions with upper GI bleeding among people resident in Wales to all NHS hospitals in Wales. Most of the study patients (94.5%) were admitted to the 18 district general hospitals in Wales, the remainder to 93 other NHS hospitals. The private sector in Wales is small and rarely receives emergency admissions. While each of the 18 district general hospitals provide in-hours endoscopy services, three provided out of hours endoscopy services as part of a formal rota during the study period, although this has been shown to have had little impact on 30 day mortality following upper GI bleeding [17]. At the end of the study period, the total population of Wales was 2.96 million. Of these, 2.34 million (78.6%) were aged >18 years and 0.531 million (17.8%) were aged >65 years [30]. Life expectancy was 77.2 years for men and 81.6 years for women [31], and the all cause mortality rate (standardised to the European population) was 718 per 100 000 population [32].

Inclusion criteria and exclusion criteria
We included adult patients aged ≥18 years who were admitted as an emergency for upper GI bleeding (where upper GI bleeding was recorded as the principal diagnosis on the first episode during the admission). Some upper GI bleeds occur as ‘inpatient bleeds’ following an admission for another disorder, for surgery or for maternities. As described previously [17], we therefore also included emergency, elective and maternity admissions for other causes (when recorded as the principal diagnosis on the first episode) but where upper GI bleeding occurred subsequently (when recorded as the principal diagnosis of a subsequent episode during the admission). The International Classification of Diseases, 10th edition (ICD-10) codes used for upper GI bleeding are listed in Appendix S1. We included each person’s first admission with upper GI bleeding after the start of the study period in April 1st 1999, through to March 31st 2004, and followed each of them up for three years, through to the end of the study, March 31st 2007.

Exposure measures
We investigated the aetiology of the upper GI bleeds using diagnoses recorded in any of the diagnostic fields during the admission (ICD-10 codes are listed in the notes to Table 1). We investigated the following major co-morbidities also using diagnoses recorded in any of the diagnostic fields; circulatory diseases (ICD-10 codes = I00-I99), all malignancies except upper gastrointestinal (C00-C14, C17.2-C97), liver disease (K70-K77), renal failure (N17-N19), chronic obstructive pulmonary disease (COPD; J40-J44) and diabetes (E10-E14). Admissions for these morbidities during three year follow-up were identified using the same ICD-10 codes, where recorded as the principal diagnosis at discharge. Subsequent admissions with upper GI bleeding during follow-up or during the 15 months before the start of the study were identified using the same criteria as for the index study bleed.

Social deprivation scores were assigned anonymously using residential postcodes at the Lower Super Output Area (LSOA; average population size of each LSOA = 1560 people) using the Welsh Index of Multiple Deprivation (WIMD) 2005 [33], which is closely compatible with the similar, widely used English Indices of Multiple Deprivation (IMD) [19]. WIMD 2005 comprises seven domains of social deprivation with the following weighting assigned to each domain: income (25% weighting), employment (25%), education (15%), health (15%), access to services (10%), housing (5%) and physical environment (5%). The LSOAs were ranked according to their WIMD 2005 score and were categorised into quintiles, with quintile I representing the 20% of least deprived LSOAs and quintile V the 20% of most deprived LSOAs.

Outcome measures and statistical analysis
The main outcome measures were mortality rates, standardised mortality ratios (SMRs) and relative survival up to three years following hospitalisation with upper GI bleeding. These included deaths that occurred in hospital during the admission with upper GI bleeding as well as those that occurred following discharge. Mortality rates were calculated using the numbers of deaths (from all causes) as the numerators and the numbers of hospitalised cases as the denominators, expressed as percentages, and were standardised directly using the study population of people admitted with upper GI bleeding. Relative survival and standardised mortality ratios (SMRs) were used to show how survival/mortality in the study patients compared with that in the general population of Wales. Relative survival was calculated as the ratio of the observed survival in the hospitalised patients compared with that in the corresponding (aged and sex matched) general population of Wales.

SMRs were calculated using the indirect method and by using two different control group comparisons. Firstly, by applying the age and sex specific mortality rates in the general adult population of Wales over the eight year study period (total n = 18.2 million) to the numbers of patients hospitalised with upper GI bleeding (n = 14 212) to obtain the expected deaths in the study population, and then by comparing the observed and expected deaths. The second control comparison was made by applying age and sex specific mortality rates, additionally matched for social deprivation and the six major co-morbidities, from the general population of adult patients in primary care data across Wales throughout the eight year study period (total n = 3.75 million), to the study patients. The primary care data was obtained through the SAIL databank [21–23], and covers one third of all general practices across Wales during the study period.

To determine factors (socio-demographic, aetiology and co-morbidities) that were most important in affecting prognosis at three years, we used multiple logistic regression. We used a parsimonious stepwise modelling approach to avoid over-fitting and multicollinearity, whereby at each stage terms added and removed from the model were tested for significance, so that the
| Aetiology/main diagnoses * | No. of patients | (% of cases) | Mean age (years) (95% CI) | % men (95% CI) | % of patients in the two most deprived quintiles (40% of people) (95% CI) |
|---------------------------|----------------|-------------|--------------------------|----------------|---------------------------------------------------------------------|
| Mallory-Weiss tear        | 894 (6.3%)     | 47.5 (46.1, 48.9) | 64.1% (60.9%, 67.3%)     | 51.1% (47.8%, 54.4%) |
| Varices – oesophageal     | 329 (2.3%)     | 58.9 (57.3, 60.5) | 65.7% (60.3%, 70.8%)     | 48.9% (43.4%, 54.4%) |
| – gastric                 | 30 (0.2%)      | 62.3 (56.4, 68.2) | 66.7% (47.0%, 83.0%)     | 53.3% (34.3%, 72.3%) |
| – overall                 | 359 (2.5%)     | 59.2 (57.8, 60.6) | 65.8% (61.1%, 70.2%)     | 49.3% (44.5%, 54.1%) |
| Ulcer – duodenal          | 1664 (11.7%)   | 63.5 (62.8, 64.3) | 63.8% (61.4%, 66.1%)     | 44.5% (42.1%, 46.9%) |
| – gastric                 | 1578 (11.1%)   | 63.4 (62.4, 64.4) | 54.3% (52.0%, 57.0%)     | 46.8% (44.3%, 49.3%) |
| – peptic, unspecified     | 192 (1.4%)     | 70.3 (68.0, 72.6) | 53.5% (46.2%, 60.7%)     | 46.9% (39.7%, 54.1%) |
| – gastrojejunal           | 23 (0.2%)      | 71.0 (61.3, 80.7) | 60.9% (38.4%, 80.7%)     | 34.8% (16.4%, 53.2%) |
| Malignancy – oesophageal  | 55 (0.4%)      | 70.1 (65.6, 74.6) | 63.6% (49.5%, 76.2%)     | 30.9% (19.1%, 42.7%) |
| – gastric/duodenal        | 92 (0.6%)      | 75.1 (71.7, 78.5) | 69.6% (59.1%, 78.8%)     | 50.0% (39.4%, 60.6%) |
| – all upper GI            | 147 (1.0%)     | 73.2 (71.2, 75.3) | 67.4% (61.1%, 72.9%)     | 42.9% (36.9%, 48.8%) |
| Oesophagitis              | 1381 (9.7%)    | 65.8 (64.8, 66.8) | 60.9% (57.9%, 63.1%)     | 44.9% (42.3%, 47.5%) |
| Gastritis & duodenitis    | 1988 (14.0%)   | 64.7 (63.9, 65.5) | 59.5% (57.3%, 61.7%)     | 47.4% (45.2%, 49.6%) |
| Other specific diseases of stomach & duodenum, including gastric antral vascular ectasia | 148 (1.0%) | 71.4 (69.4, 73.4) | 48.6% (40.3%, 57.0%) | 42.6% (34.5%, 50.7%) |
| Complications of anti-coagulants | 101 (0.7%) | 74.1 (71.8, 76.2) | 48.9% (38.4%, 58.7%) | 46.5% (36.5%, 56.5%) |
| Complications of analgesics, antipyretics & anti-inflammatory drugs (AAAs) | 405 (2.8%) | 70.9 (69.2, 72.6) | 48.9% (43.9%, 53.9%) | 38.8% (34.0%, 43.6%) |
| Other & unspecified aetiologies | 6354 (44.7%) | 652 (64.7, 65.7) | 58.7% (57.7%, 59.9%) | 46.1% (44.9%, 47.4%) |
| All cases                 | 14 212 (100%)  | 64.1 (63.8, 64.4) | 53.9% (52.7%, 54.3%)     | 48.0% (47.2%, 48.8%) |

**Notes**

*The ICD-10 codes used for the aetiology/main diagnoses were as follows:
Mallory-Weiss tear (K22.6), varices – oesophageal (R85), varices – gastric (R86.4), ulcer – duodenal (K26), ulcer – gastric (K25), ulcer – peptic, unspecified (K27), ulcer – gastrojejunal (K28), malignancy – oesophageal (C15), malignancy – gastric/duodenal (C16, C17.0), oesophagitis (K00), K21.1, K22.1), gastritis & duodenitis (K29), other specific diseases of stomach & duodenum, including gastric antral vascular ectasia (K31.8), complications of anti-coagulants (Y44.2), complications of analgesics, antipyretics & anti-inflammatory drugs (Y45).

doi:10.1371/journal.pone.0049507.t001
### Table 2. Numbers of patients, numbers of deaths at three years, crude mortality rates and standardised mortality ratios (SMRs) for people hospitalised with upper GI bleeding according to prognostic factors.

| Three year follow-up | Comparison with age and sex matched general population | Comparison with age, sex, deprivation and co-morbidity matched GP population |
|----------------------|--------------------------------------------------------|----------------------------------------------------------------------------|
|                      | No. of patients | No. of deaths | Crude mortality rate (%) | SMR | 95% CI | SMR | 95% CI  |
| All cases            | 14 212         | 5215          | 36.7% | 2.6 | (2.5, 2.7) | 2.1 | (2.0, 2.2) |
| **Age group (years)**| ****           | ****          | ****  | **** | ****  | **** | ****   |
| 18–24                | 656            | 7             | 1.1%  | 5.7 | (2.3, 10.8) | 10.5 | (4.2, 19.7) |
| 25–34                | 993            | 42            | 4.2%  | 14.2 | (10.2, 18.9) | 7.0 | (5.0, 9.3) |
| 35–44                | 1288           | 133           | 10.3% | 22.8 | (19.1, 26.8) | 9.3 | (7.8, 11.0) |
| 45–54                | 1418           | 248           | 17.5% | 16.8 | (14.8, 18.9) | 7.8 | (6.9, 8.9) |
| 55–64                | 1628           | 439           | 27.0% | 9.9  | (9.0, 10.8)  | 6.5 | (5.9, 7.1)  |
| 65–74                | 2595           | 972           | 37.5% | 5.0  | (4.7, 5.3)   | 4.1 | (3.8, 4.4)  |
| 75–84                | 3536           | 1862          | 52.7% | 2.7  | (2.6, 2.8)   | 2.2 | (2.1, 2.3)  |
| 85+                  | 2098           | 1512          | 72.1% | 1.5  | (1.4, 1.5)   | 1.2 | (1.2, 1.3)  |
| **Sex**              | ****           | ****          | ****  | **** | ****  | **** | ****   |
| Men                  | 7605           | 2633          | 34.6% | 2.9  | (2.8, 3.0)   | 2.1 | (2.0, 2.2)  |
| Women                | 6603           | 2582          | 39.1% | 2.4  | (2.3, 2.5)   | 2.2 | (2.1, 2.3)  |
| **Aetiology/main diagnoses** | ****          | ****          | ****  | **** | ****  | **** | ****   |
| Mallory-Weiss tear   | 894            | 119           | 13.3% | 2.3  | (1.9, 2.7)   | 1.8 | (1.5, 2.1)  |
| Varices – oesophageal| 329            | 167           | 50.8% | 7.6  | (6.5, 8.8)   | 5.7 | (4.9, 6.6)  |
| – gastric            | 30             | 21            | 70.0% | 7.2  | (4.5, 10.5)  | 5.4 | (3.4, 7.2)  |
| – overall            | 359            | 188           | 52.4% | 7.5  | (6.5, 8.6)   | 5.7 | (4.9, 6.5)  |
| Ulcer – duodenal     | 1664           | 638           | 38.3% | 2.5  | (2.3, 2.7)   | 2.0 | (1.9, 2.2)  |
| – gastric            | 1578           | 648           | 41.1% | 2.6  | (2.4, 2.8)   | 2.1 | (1.9, 2.3)  |
| – peptic, unspecified| 192            | 77            | 40.1% | 2.4  | (1.9, 3.0)   | 2.0 | (1.5, 2.4)  |
| – gastrojejunal      | 23             | 12            | 52.2% | 3.1  | (1.6, 5.0)   | 2.4 | (1.2, 4.0)  |
| Malignancy – oesophageal| 55           | 52            | 94.5% | 7.2  | (5.3, 9.2)   | 5.8 | (4.3, 7.5)  |
| – gastric/duodenal   | 92             | 87            | 94.6% | 5.2  | (4.1, 6.3)   | 4.1 | (3.3, 5.1)  |
| – all upper GI       | 147            | 139           | 94.6% | 5.8  | (4.9, 6.8)   | 4.6 | (3.9, 5.4)  |
| Oesophagitis         | 1381           | 527           | 38.2% | 2.6  | (2.4, 2.9)   | 2.1 | (2.0, 2.3)  |
| Gastritis & duodenitis| 1988         | 676           | 34.0% | 2.6  | (2.4, 2.8)   | 2.1 | (2.0, 2.3)  |
| Other specific diseases of stomach & Duodenum including gastric antral vascular ectasia | 148 | 62 | 41.9% | 2.3 | (1.8, 3.0) | 1.9 | (1.5, 2.4) |
| Complications of anti-coagulants | 101 | 55 | 54.5% | 3.0 | (2.2, 3.8) | 2.5 | (1.9, 3.2) |
### Table 2. Cont.

| Complications | No. of patients | No. of deaths | Crude mortality rate (%) | SMR  | 95% CI | SMR  | 95% CI |
|---------------|----------------|---------------|--------------------------|------|--------|------|--------|
| Complications of analgesics, antipyretics & anti-inflammatory drugs (AAAs) | 405 | 139 | 34.3% | 1.9 (1.6, 2.2) | 1.6 (1.3, 1.8) |
| Other & unspecified aetiologies | 6354 | 2370 | 37.3% | 2.7 (2.6, 2.8) | 2.2 (2.1, 2.3) |
| Major co-morbidities* | | | | | |
| Circulatory diseases | 4660 | 2443 | 52.4% | 2.8 (2.7, 2.9) | 2.3 (2.2, 2.4) |
| Malignancies (all except upper GI) | 748 | 667 | 89.2% | 5.2 (4.8, 5.6) | 4.1 (3.8, 4.5) |
| Liver disease | 590 | 355 | 60.2% | 13.5 (12.2, 15.0) | 10.0 (9.0, 11.1) |
| COPD | 504 | 322 | 63.9% | 3.5 (3.1, 3.8) | 2.8 (2.5, 3.1) |
| Diabetes | 1226 | 625 | 51.0% | 3.2 (3.0, 3.5) | 2.6 (2.4, 2.8) |
| Renal failure | 403 | 307 | 76.2% | 3.8 (3.4, 4.2) | 3.0 (2.7, 3.4) |
| Social deprivation | | | | | |
| I (most affluent quintile) | 2045 | 795 | 38.9% | 2.3 (2.2, 2.5) | 1.9 (1.8, 2.0) |
| II | 2404 | 916 | 38.1% | 2.5 (2.3, 2.6) | 2.0 (1.9, 2.2) |
| III | 2941 | 1112 | 37.8% | 2.5 (2.4, 2.6) | 2.1 (1.9, 2.2) |
| IV | 3130 | 1131 | 36.1% | 2.7 (2.5, 2.8) | 2.2 (2.1, 2.3) |
| V (most deprived quintile) | 3692 | 1261 | 34.2% | 3.1 (2.9, 3.2) | 2.5 (2.4, 2.6) |
| Inpatient bleed | | | | | |
| No | 13 309 | 4728 | 35.5% | 2.6 (2.5, 2.6) | 2.1 (2.1, 2.2) |
| Yes | 903 | 487 | 53.9% | 3.1 (2.8, 3.3) | 2.5 (2.3, 2.7) |
| Previous admissions with upper GI bleeding in the 15 months before the study | | | | | |
| None | 13 851 | 5062 | 36.5% | 2.6 (2.5, 2.7) | 2.1 (2.1, 2.2) |
| 1 | 289 | 132 | 45.7% | 3.5 (2.9, 4.1) | 2.8 (2.3, 3.3) |
| 2 | 39 | 16 | 41.0% | 3.9 (2.2, 6.0) | 3.1 (1.8, 4.8) |
| 3+ | 33 | 5 | 15.2% | 3.7 (1.2, 7.7) | 2.9 (0.9, 6.0) |
| Admissions with upper GI bleeding during three year follow-up | | | | | |
| 1 | 13 019 | 4736 | 36.4% | 2.6 (2.5, 2.6) | 2.1 (2.0, 2.2) |
| 2 | 985 | 392 | 39.8% | 3.1 (2.8, 3.4) | 2.6 (2.3, 2.8) |
| 3 | 154 | 65 | 42.2% | 3.8 (2.9, 4.7) | 3.2 (2.4, 4.0) |
| 4+ | 54 | 22 | 40.7% | 4.5 (2.8, 6.6) | 3.7 (2.3, 5.4) |
Table 2. Cont.

| Three year follow-up | Comparison with age and sex matched general population | Comparison with age, sex, deprivation and co-morbidity matched GP population |
|----------------------|------------------------------------------------------|------------------------------------------------------------------|
|                      | No. of patients | No. of deaths | Crude mortality rate (%) | SMR  | 95% CI | SMR  | 95% CI |
| Admissions for major morbidities during three year follow-up |
| Circulatory diseases - No | 12 935 | 4639 | 35.1% | 2.5 | (2.4, 2.6) | 2.1 | (2.1, 2.2) |
| - Yes | 12 77 | 676 | 52.9% | 4.1 | (3.8, 4.5) | 3.3 | (3.0, 3.5) |
| All malignancies except upper GI - No | 13 601 | 4721 | 34.7% | 2.5 | (2.4, 2.6) | 2.0 | (2.0, 2.1) |
| - Yes | 611 | 494 | 80.9% | 5.3 | (4.9, 5.8) | 4.2 | (3.9, 4.6) |
| Liver disease - No | 13 931 | 5060 | 36.3% | 2.6 | (2.5, 2.6) | 2.1 | (2.0, 2.1) |
| - Yes | 281 | 155 | 55.2% | 18.5 | (15.7, 21.5) | 13.1 | (11.1, 15.2) |
| COPD - No | 14 046 | 5117 | 36.4% | 2.6 | (2.5, 2.7) | 2.1 | (2.1, 2.2) |
| - Yes | 166 | 98 | 59.0% | 3.7 | (3.0, 4.4) | 2.9 | (2.4, 3.5) |
| Diabetes - No | 14 107 | 5171 | 36.7% | 2.6 | (2.5, 2.7) | 2.1 | (2.1, 2.2) |
| - Yes | 105 | 44 | 41.9% | 4.0 | (2.9, 5.2) | 3.2 | (2.3, 4.2) |
| Renal failure - No | 14 126 | 5155 | 36.5% | 2.6 | (2.5, 2.7) | 2.1 | (2.1, 2.2) |
| - Yes | 86 | 60 | 69.8% | 6.6 | (5.0, 8.4) | 4.9 | (3.7, 6.2) |

Notes
*The ICD-10 codes used for the co-morbidities and the admissions for morbidities were as follows; circulatory diseases (ICD-10 =I00-I99), all malignancies except upper GI (C00-C14, C17.2-C97), liver disease (K70-K77), COPD (J40-J44), diabetes (E10-E14) and renal failure (N17-N19).
doi:10.1371/journal.pone.0049507.t002
final model comprised only of those terms that had significant independent effect on mortality. Significance was measured at the 5% level, and a bonferroni correction was used to assess multiple comparisons.

Results

There were 14 212 people admitted with upper GI bleeding from 1999 to 2004. Most (13 309; 94%) presented for admission with upper GI bleeding, 903 (6.4%) occurred as inpatient bleeds, and the majority (7605; 54%) were men. The mean age of the patients was 64.1 years (standard deviation = 20.3 years; range = 18–103 years). Women were older (p < 0.001) than men (mean 68.5 years vs 60.4 years).

The most common diagnoses for the bleeds were peptic ulcer (3434; 24%) – including duodenal ulcer (1664; 12%), gastric ulcer (1578; 11%) and unspecified peptic ulcer (192; 1.4%) – followed by gastritis & duodenitis (1988; 14%), oesophagitis (1381; 10%) and Mallory-Weiss tear (894; 6.3%; Table 1).

Table 1 also shows socio-demographic characteristics of the 14 212 patients according to aetiology of the bleed. Mallory-Weiss tear and oesophageal varices aetologies were most common among younger patients, gastric/duodenal malignancy and complications of anti-coagulants among older patients. Upper GI malignancy and varices were most prevalent among men, while Mallory-Weiss tear and gastric varices tended to be most common among the two most socially deprived quintiles (Table 1). For most aetiologies - and for upper GI bleeds overall - patients were disproportionally among the two most deprived quintiles (>40% of patients).

Mortality up to three years following hospital admission

At three years after admission, there were 5215 deaths from all causes (mortality rate = 36.7%; Table 2). Mortality as an inpatient was 9.7% and mortality at 30 days was 10.0%. Age specific mortality increased from 1.1% among people aged 18-24 years to 72% for people 85+ years (Table 2). Mortality ranged from 13% for Mallory-Weiss tear to 34% for gastritis & duodenitis, 38–41% for duodenal ulcer, gastric ulcer and oesophagitis, 52% for varices and 95% for upper GI malignancy (Table 2). Mortality was also higher for bleeds that occurred as inpatients (54%) than for bleeds presenting at admission (36%).

Age adjusted mortality was 27% higher among women than men (95% CI = 22–33%). Age and sex adjusted mortality was 28% higher (95% CI = 13–45%) for the most deprived quintile of patients than the most affluent quintile. Mortality was also increased for patients who had previous admissions for upper GI bleeding in the 15 months before the study period, or who had subsequent admissions with upper GI bleeding or for other major disorders during the three year follow-up (Table 2).

Compared with the age and sex matched general population (SMR = 1.0), all cause mortality was increased 27-fold during the first month after admission (Figure 1). This increased risk fell to 4.3 during month four, but mortality remained significantly elevated during every month throughout the three years following admission.

Mortality at three years was increased when compared with the age and sex matched general Welsh population (SMR = 2.61), and also when compared with the age, sex, social deprivation and co-morbidity matched Welsh population from primary care (SMR = 2.14; Table 2). Mortality at three years was also increased for all aetiologies, most strongly for oesophageal varices (SMR = 7.6 compared with the general population), followed by oesophageal malignancies and gastric varices (both SMRs = 7.2) and most weakly for Mallory-Weiss tear (SMR = 2.3; Table 2).

Relative survival - compared with the general population - was best for Mallory-Weiss tear aetiology and worst for malignancies and varices (Figure 2). Relative survival was substantially higher for duodenal ulcer than for gastric ulcer during the first few months after admission, but was worse for gastric ulcer in the longer term. For ‘complications of analgesics, antipyretics & anti-inflammatory drugs’ and duodenal ulcer aetiologies, survival almost levelled off to that in the general population, but for the other aetiologies, it remained worse throughout the three year follow up (Figure 2).

Based on underlying cause of death, the causes of 1920 of these deaths from January 2003 onwards were upper GI bleeding (128 deaths; 6.7%), ischaemic heart disease (283; 14.7%), stroke (185;
9.6%), other circulatory diseases (156; 8.1%), GI malignancies (182; 9.5%), liver disease (114; 5.9%), other GI diseases (77; 4.0%), other malignancies (225; 11.7%), pneumonia (133; 6.9%), COPD (66; 3.4%) and various other disorders (371; 19.3%).

Predictors of mortality at three years

Using multivariate analysis (Table 3), the most important predictors of mortality at three years, with significant independent effect were as follows. Firstly, the age of the patient. There was a 53-fold increased risk of mortality for people aged 85+ years when compared with patients aged <40 years (Table 3). Secondly, aetiology of the bleed. There were significantly increased risks of mortality of 48 for oesophageal malignancy, 32 for gastric/duodenal malignancy and 2.8 for gastric varices aetiologies, when compared with all other & unspecified bleeds. There were also significantly reduced risks of 46% for Mallory-Weiss tear, 31% for ‘complications of analgesics, antipyretics & anti-inflammatory drugs’ and 18% for gastritis & duodenitis aetiologies. Third, patient co-morbidities. There were significantly increased risks of 15 for patients with non-upper GI malignancies, 7.9 for liver disease and 3.9 for renal failure co-morbidities when compared with patients without these co-morbidities. Fourth, ‘inpatient bleeds’ that occur as an inpatient, with a 31% increased risk compared with bleeds at admission. Fifth, social deprivation, with a 29% increased risk for patients in the most deprived quintile V compared with the most affluent quintile I. Finally, the sex of the patient.

Figure 2. Relative survival during the three years following hospital admission with upper GI bleeding, compared with that in the general population, according to the aetiology of the bleed. The horizontal line in bold at 100% denotes relative survival in the general population. Vertical bars on the far right represent 95% confidence intervals. Relative survival is standardised for age group and sex. Complications of AAAs = Complications of analgesics, antipyretics & anti-inflammatory drugs.

doi:10.1371/journal.pone.0049507.g002
Table 3. Multivariate analysis showing prognostic factors with significant and independent influence on mortality at three years following hospital admission with upper GI bleeding.

| Prognostic factor | Adjusted Odds ratio * | (95% CI) † | P-value ‡ |
|-------------------|-----------------------|-------------|-----------|
| **Age group**     |                       |             |           |
| <40               | 1.00                  | Ref         | <0.001    |
| 40–44             | 1.77                  | (1.26, 2.48) |           |
| 45–49             | 2.39                  | (1.76, 3.24) |           |
| 50–54             | 3.26                  | (2.47, 4.31) |           |
| 55–59             | 3.94                  | (2.99, 5.18) |           |
| 60–64             | 5.64                  | (4.36, 7.30) |           |
| 65–69             | 7.01                  | (5.50, 8.94) |           |
| 70–74             | 10.1                  | (8.00, 12.7) |           |
| 75–79             | 14.5                  | (11.6, 18.2) |           |
| 80–84             | 23.1                  | (18.4, 29.0) |           |
| 85+               | 52.9                  | (42.2, 66.4) |           |
| **Sex**           |                       |             | <0.001    |
| Women             | 1.00                  | Ref         |           |
| Men               | 1.25                  | (1.15, 1.37) |           |
| **Social deprivation** |                 |             | 0.001     |
| I (most affluent quintile) | 1.00                | Ref         |           |
| II                | 1.06                  | (0.92, 1.23) |           |
| III               | 1.05                  | (0.92, 1.21) |           |
| IV                | 1.14                  | (0.99, 1.31) |           |
| V (most deprived quintile) | 1.29                | (1.12, 1.47) |           |
| **Inpatient bleed** |                     |             |           |
| No                | 1.00                  | Ref         |           |
| Yes               | 1.31                  | (1.12, 1.54) | 0.001     |
| **Aetiology/main diagnoses** |             |             |           |
| All other & unspecified aetiologies | 1.00              | Ref         |           |
| Mallory-Weiss tear | 0.54                 | (0.43, 0.69) | <0.001    |
| Varices – gastric  | 2.80                  | (1.12, 7.01) | 0.028     |
| Malignancy – oesophageal | 48.0                | (14.3, 160) | <0.001    |
| Malignancy – gastric/duodenal | 32.2               | (12.8, 80.8) | <0.001    |
| Gastritis & duodenitis | 0.82                | (0.73, 0.92) | 0.001     |
| Complications of analgesics, antipyretics & anti-inflammatory drugs (AAAs) | 0.69     | (0.54, 0.87) | 0.002     |
| **Major co-morbidities** |             |             |           |
| None              | 1.00                  | Ref         |           |
| Circulatory diseases | 1.49                | (1.36, 1.62) | <0.001    |
| Malignancies (all except upper GI) | 15.4               | (11.8, 20.1) | <0.001    |
| Liver disease     | 7.89                  | (6.44, 9.68) | <0.001    |
| COPD              | 2.20                  | (1.79, 2.71) | <0.001    |
| Diabetes          | 1.35                  | (1.18, 1.55) | <0.001    |
| Renal failure     | 3.93                  | (3.02, 5.12) | <0.001    |

Notes
*Odds ratios for sex are adjusted for age group, odds ratios for social deprivation, inpatient bleed, aetiology/main diagnoses, and major c-morbidities are adjusted for age group and sex
†Ref = Reference category
‡When applying the Bonferroni correction to adjust for the multiple comparisons (p = 0.0031), all terms in this model remained statistically significant with the exception of gastric varices (which was based on only 30 cases). None of the two-way interaction effects between these terms were significant when applying the Bonferroni correction (p = 0.0004) or at the p = 0.001 level.

doi:10.1371/journal.pone.0049507.t003
patient, with a 25% increased risk for men compared with women. When using a bonferroni correction for the multiple comparisons (p = 0.0031), all of these factors remained significant except gastric varices.

**Discussion**

The aim of this study was to establish, for the first time, longer term prognosis for people hospitalised with upper GI bleeding and its relationship with aetiology, co-morbidities and socio-demographic factors. We found that overall mortality at three years following admission with upper GI bleeding was high at 36.7%. It was highest for upper GI malignancies (95%) and varices (52%; particularly gastric varices, 70%) aetiologies. Compared with the general population, mortality was increased 27-fold during the first month after admission, this SMR fell to 4.3 after three months, but it remained elevated during every month in the three years following admission. Mortality was associated with social deprivation, with highest rates among people in the most deprived quintile. Admission with upper GI bleeding thus carries both a high early and late mortality.

Major strengths of this study are that it provides new evidence on longer term prognosis for upper GI bleeding. Secondly, it is one of the largest studies of upper GI bleeding, covering more than 14,000 people who were hospitalised. Thirdly, it is based on systematic record linkage to enable reliable longer term follow-up and to identify deaths that occur following discharge from hospital. The record linkage, principal inpatient diagnoses and ascertainment of mortality have been validated previously and have been shown to be respectively >99.8%, >90% and >98% accurate [21,29].

Limitations of the study are, firstly, the administrative inpatient data lacks detailed information about disease history, pathology, severity of bleeding and treatment, although some of these factors are of less importance for this study of mortality in the longer term following admission. The measures of prognosis reported here are those from the index admission with upper GI bleeding and we recognise that some of these may occur late in the natural history of upper GI disease. However, since 83% of the study patients were hospitalised once only with upper GI bleeding during the five year inpatient period studied, this should affect a minority of cases.

As in other recent studies that have used national administrative inpatient data [14,17–19], the recording of aetiologies and major co-morbidities would be incomplete in some cases. As per convention in most studies, deaths from all causes were included when investigating mortality rates, as deaths specifically from upper GI bleeding accounted for only a small minority of all deaths, which has been found for many other conditions [34]. The study was restricted to NHS hospitals, although the private sector is small and receives few emergencies for upper GI bleeding. Although it is also possible that we may have missed some upper GI bleeds through the limitations of hospital and ICD coding, and included some lower GI bleeds, these discrepancies should be small [17]. The longer term mortality follow-up to three years – instead of the usual inpatient or 30 days – was used to investigate the prognostic impact of aetiology, co-morbidity and socio-demographic factors – rather than treatment and hospital-related factors, which are usually of less relevance beyond the acute phase and inpatient stay. Our cohort should not be affected substantially by attrition over the three year follow-up, as migration out of Wales was about 0.3% per annum during 2005 and 2006, compared with 0.5% immigration [35], and is lower among older age groups who are most frequently affected by upper GI bleeds.

Early mortality for upper GI bleeding (as an inpatient or at 30 days) has been shown to vary according to aetiology from <5% for Mallory-Weiss tear to about 10% for peptic ulcer, 15-25% for varices and >20% for upper GI malignancies [3–6,17]. There was extremely poor prognosis (95% mortality at three years) for upper GI malignancies. We also found that late mortality is very high for varices (32%) - which is consistent with other studies that have reported dismal prognosis for decompensated liver cirrhosis [36–40]. Although relatively uncommon (50 cases), the higher mortality for gastric varices rather than for oesophageal varices may indicate more severe portal hypertension and bleeding, as well as greater difficulty in securing haemostasis through therapeutic endoscopy.

Our inpatient mortality rate of 9.7% compares with rates of 4.6%, 9.4%, 10.3% and 15.2% from four previous single centre studies in Wales in recent years [2], and with 10.0% in the recent UK audit [3]. The aetiology distribution of the diagnosed bleeds is also broadly comparable with these previous studies. Previous studies, including ours, have reported no significant differences in early mortality according to social deprivation [6,17,19]. At three year follow up, we found significantly higher mortality among the most deprived quintile of patients than the most affluent. This apparent widening of mortality differentials across social groups with longer durations of follow-up after admission reflects general social inequalities in health outcomes. The higher age adjusted mortality among men - compared with women - reflects a higher proportion of highest risk bleeds from varices and malignancies among men than women. The fact that mortality was elevated when a co-morbidity-matched comparison was made with patients from primary care, suggests that the co-morbidities among hospitalised upper GI bleed patients are much more severe than among primary care patients, and would also reflect that a very small minority of high risk people are not registered with GPs.

Upper GI bleeding is one of the most important emergency disorders with high rates of mortality during the acute phase. When compared with the general population, we found that mortality was increased 27-fold during the first month after admission, which is comparable with that found in a study of acute pancreatitis (30-fold increase) [41]. After three months, the increased risk of mortality had fallen to 4.3, but it remained elevated during each month of the three years after admission. This longer term increased risk of mortality is partly due to very poor prognosis for malignancy and variceal aetiologies, although it also reflects an impact of high levels of social deprivation and chronic co-morbid disease among people with upper GI bleeding. Our findings are broadly concordant with the existing but very limited evidence for late mortality. For example, our mortality rate of 41% at three years for peptic ulcer bleeds compares with 29% reported for people aged 60 years and over in the Nottingham region at (an average of) 34 months follow-up [20].

Survival over the three years was substantially poorer than in the general population for most aetiologies of bleeding, with the possible exception of complications of analgesics, antiinflammatory drugs & anti-inflammatory drugs and duodenal ulcers, which were both less prevalent among deprived quintiles than most of the other aetiologies. Relative survival was worse for duodenal ulcer than for gastric ulcer in the first few months after admission, but it was better than for gastric ulcer bleeds in the longer term. This finding is consistent with a large single-centre study of surgery for peptic ulcer which found increased longer term mortality for gastric ulcer but not for duodenal ulcer [42].

The most important predictors of poor prognosis at three years were older age groups, malignancy and gastric variceal aetiologies, inpatient bleeds, male patients, high levels of social deprivation
and the following co-morbidities; non-upper GI malignancies, liver disease and renal failure. These show strong similarities with the Rockall score (which includes older age groups, shock, renal failure, liver failure, metastatic cancer, malignancy aetiology and evidence of bleeding at endoscopy as the strongest predictors of poor prognoses in the short term) [46], although were unable to investigate shock and evidence of bleeding at endoscopy accurately. Our findings also suggest that social deprivation is an important independent predictor of prognosis in the longer term following admission.

Supporting information
Appendix S1 ICD-10 codes used for upper GI bleeding.

References
1. Palmer KR (2005) Haematemesis and melena. Medicine 31: 19–24.
2. Williams JG, Roberts SE, Ali MF, Cheung WY, Cohen DR, et al. (2007) Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a nationwide study. Gut 56 Suppl 1: i–i13.
3. Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, et al. (2011) Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 60: 1327–1335.
4. Rockall TA, Logan RFA, Devlin HB, Northfield TC (1995) Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. BMJ 311(699): 222–226.
5. Vreeburg EM, Snell P, de Bruijne JW, Bartlesman JF, et al. (1997) Acute upper gastrointestinal bleeding in the Amsterdam area: incidence, diagnosis, and clinical outcome. Am J Gastroenterol 92: 256–261.
6. Blatchford O, Davidson I, Murray W, Blatchford M, Pell J (1997) Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study BMJ 315: 510–514.
7. Kapur KC, Green JT, Turner RG, Swift J, Srivastava ED, et al. (1998) Auditing mortality from upper gastrointestinal haemorrhage: impact of a high dependency unit. J R Coll Physicians Lond 32: 246–250.
8. van Leerdam ME, Vreeburg EM, Raams EA, Geradea AA, Tijssen JG, et al. (2003) Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol 98: 1494–1499.
9. Barkun A, Sabbah S, Emn R, Armstrong D, Gregor J (2004) The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 99: 1238–46.
10. Sanders DS, Perry MJ, Jones SG, McFarlane E, Johnson AG, et al. (2004) Effectiveness of an upper gastrointestinal haemorrhage unit: a prospective analysis of 900 consecutive cases using the Rockall score as a method of risk standardisation. Eur J Gastroenterol Hepatol 16: 487–494.
11. Di Fiore F, Leclere S, Merle V, Herve S, Duhamel C, et al. (2005) Changes in characteristics and outcome of acute upper gastrointestinal haemorrhage: a comparison of epidemiology and practices between 1996 and 2000 in a multicentre French study. Eur J Gastroenterol Hepatol 17: 641–647.
12. Targowski LE, Nubarahma A (2006) Trends in management and outcomes of acute nonvarical upper gastrointestinal bleeding’ 1993–2003. Clin Gastroenterol Hepatol 4: 1459–1466.
13. Mamo R, Koch M, Cipolletta L, Capurso L, Peri A (2008) Predictive factors of mortality from nonvarical upper gastrointestinal hemorrhage: a multicenter study. Am J Gastroenterol 103: 1639–1647.
14. Ananthakrishnan AN, McGinley EL, Sarac K (2009) Outcomes of weekend admissions for upper gastrointestinal hemorrhage: a nationwide analysis. Clin Gastroenterol Hepatol 7: 296–302.
15. Ahlberg K, Hoglund P, Kim WH, von Hodstein CS (2010) Impact of aspirin, NSAIDs, warfarin, corticosteroids and SSRIs on the site and outcome of non-varical upper and lower gastrointestinal bleeding. Scand J Gastroenterol 45: 1404–1415.
16. Lanas A, Aasbakken L, Fonseca J, Mungan ZA, Papathodoridis GV (2011) Clinical predictors of poor outcomes among patients with nonvarical upper gastrointestinal bleeding in Europe. Aliment Pharmacol Ther 33: 1223–1233.
17. Button LA, Roberts SE, Evans PA, Goldacre MJ, Akbari A, et al. (2011) Hospitalised life-threatening bleeding and case fatality for upper gastrointestinal bleeding from 1999 to 2007: a record linkage study. Aliment Pharmacol Ther 33: 64–76.
18. Crooks C, Card T, West J (2011) Reductions in 28-day mortality following hospital admission for upper gastrointestinal hemorrhage. Gastroenterology 141: 62–70.
19. Crooks CJ, West J, Card TR (2012) Upper gastrointestinal haemorrhage and deprivation: a nationwide cohort study of health inequality in hospital admissions. Gut 61: 514–520.
20. Hudson N, Faulkner G, Smith SJ, Langman MJ, Hawkey CJ, et al. (1995) Late mortalityin elderly patients surviving acute peptic ulcer bleeding. Gut 37: 177–81.
21. Lyons RA, Jones KH, John G, Brooks CJ, Verplancke JP, et al. (2009) The SAIL databank: linking multiple: health and social care datasets. BMC Med Inform Decis Mak 9: 3.
22. Ford DV, Jones KH, Verplancke JP, Lyons RA, John G, et al. (2009) The SAIL Databank: building a national architecture for e-health research and evaluation. BMC Health Serv Res 9: 3.
23. Brooks CJ, Cooksey R, Lyons RA, Jones KH, Button AJ, et al. (2010) The prescribed duration algorithm: utilising ‘free text’ from multiple primary care electronic systems. Pharmacoepidemiol Drug Saf 19: 983–989.
24. Lyons RA, Jones SJ, Deacon T, Heaven M (2003) Socioeconomic variation in injury in children and older people: a population based study. Inj Prev 9: 33–37.
25. Lyons RA, Ward H, Beunt H, Macey S, Thorre R, et al. (2008) Using multiple datasets to understand trends in serious road traffic casualties. Accid Anal Prev 40: 1406–1410.
26. Paranjothy S, Fone D, Mann M, Dunstan F, Evans E, et al. (2009) The incidence and aetiology of epistaxis in infants: a population-based study. Arch Dis Child 94: 421–424.
27. Button LA Roberts SE, Goldacre MJ, Akbari A, Williams JG (2016) Hospitalised prevalence and 5 year mortality for IBD: record linkage study. World J Gastroenterol 16: 431–438.
28. Roberts SE, Button LA, Hopkin JM, Goldacre MJ, Lyons RA, et al. (2012) Influence of social deprivation and air pollutants on serious asthma. Eur Respir J 40: 785–790.
29. Roberts SE, Williams JG, Cohen DR, Akbari A, Groves S, et al. (2011) Feasibility of using routinely collected inpatient data to monitor quality and inform choice: a study using the UK Inflammatory Bowel Disease audit. Frontline Gastroenterol 2: 153–159.
30. Office for National Statistics. Population Estimates for UK, England and Wales, Scotland and Northern Ireland - mid 2007. Available: http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-213833. Accessed 2012 Sep 2.
31. Welsh Assembly Government (2010) Life expectancy, 2007–9. Cardiff: Welsh Assembly Government SB 94/2010.
32. Public Health Wales Observatory. Mortality data: main causes. Available: http://www.wales.nhs.uk/sitesplus/9222/page/53914. Accessed 2012 Sep 2.
33. Welsh Government: Welsh Index of Multiple Deprivation (WIMD). Available: http://wales.gov.uk/topics/statistics/theme/wimd/?lang=en. Accessed 2012 Sep 2.
34. Goldacre MJ (1993) Cause-specific mortality: understanding uncertain tips of the disease iceberg. J Epidemiol Community Health 47: 491–496.
35. Office for National Statistics (2007) International Migration, 2006. Available: http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-213833. Accessed 2012 Sep 2.
36. Saunders JB, Walters JR, Davies AP, Paton A (1981) A 20-year prospective study of the use of alcohol and the liver: a nationwide cohort study in Denmark. J Clin Epidemiol 56: 88–93.
37. Parvez P, Jepson P, Atkins P, Pakrasi N, Kothari R (2008) Trends in mortality after admission for liver cirrhosis in an English population from 1968 to 1999. Gut 54: 1615–1621.
38. Swensen HT, Thulstrup AM, Mellemkjaer L, Jepsen P, Christensen E, et al. (2004) Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark. J Clin Epidemiol 56: 168–173.
39. Jepsen P, Otto P, Andersen PK, Thulstrup A (2010) Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 51: 1675–1682.
40. Fleming KM, Aithal GP, Card TR, West J (2012) All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver International 32: 79–84.

Acknowledgments
The authors are grateful to Ashley Akbari and Mark Atkinson, College of Medicine, Swansea University, for data programming and extraction; and the Health Information Research Unit (HIRU), College of Medicine, Swansea University, for preparing and providing access to the project specific linked datasets from the Secure Anonymised Information Linkage (SAIL) system, which is funded by the Wales Office of Research and Development.

Author Contributions
Conceived and designed the experiments: SER JGW. Performed the experiments: SER JGW LAB. Analyzed the data: LAB SER. Contributed reagents/materials/analysis tools: SER JGW. Wrote the paper: SER JGW LAB.

Mortality following Upper GI Bleeding
41. Goldacre MJ, Roberts SE (2004) Hospital admission for acute pancreatitis in an English population, 1963–98: database study of incidence and mortality. BMJ 328(7454): 1466–1469.

42. Stael von Holstein C, Anderson H, Alhberg K, Huld B (1997) The significance of ulcer disease on late mortality after partial gastric resection. Eur J Gastroenterol Hepatol 9: 33–40.

43. Rockall TA, Logan RF, Devlin HB, Northfield TC (1996) Risk assessment after acute upper gastrointestinal haemorrhage. Gut 38: 316–321.